Itf Therapeutics Llc

Itf Therapeutics Llc company information, Employees & Contact Information

ITF Therapeutics is the US-based rare disease division of Italfarmaco S.p.A. Founded in 1938 in Milan, Italy, Italfarmaco is a private global pharmaceutical company that has led the successful development of many innovative therapeutic products approved for use by patients around the world. The company operates in more than 90 countries on five continents and continues to advance promising research to address unmet medical needs in a wide range of therapeutic areas. In January 2024, Italfarmaco launched ITF Therapeutics as a new division in the United States with a focus on the development and commercialization of products to treat rare diseases. Building on a legacy grounded in collaboration and innovation, ITF Therapeutics strives to partner with leaders from the US patient advocacy and treatment communities to ensure that our programs reflect and support their unique needs and goals. The establishment of ITF Therapeutics reflects Italfarmaco’s goal to build a world- class team of experts who share a passion to make a positive impact for rare disease communities.

Company Details

Employees
70
Founded
-
Address
Concord, Ma, Us
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Concord, MA
Looking for a particular Itf Therapeutics Llc employee's phone or email?

Itf Therapeutics Llc Questions

News

ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts - PR Newswire

ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts PR Newswire

ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference - Yahoo Finance

ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference Yahoo Finance

ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer - citybiz

ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer citybiz

Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy - Business Wire

Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy Business Wire

ITF Therapeutics LLC Announces Multiple Data Presentations at 2025 MDA Clinical and Scientific Conference - PR Newswire

ITF Therapeutics LLC Announces Multiple Data Presentations at 2025 MDA Clinical and Scientific Conference PR Newswire

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy - PR Newswire

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy PR Newswire

Top Itf Therapeutics Llc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant